Patritumab deruxtecan
U31402-A-U201
Phase 2 small_molecule active
Quick answer
Patritumab deruxtecan for Metastatic or Locally Advanced EGFR mutated Non-Small Cell Lung Cancer (NSCLC) is a Phase 2 program (small_molecule) at Daiichi Sankyo Europe GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Daiichi Sankyo Europe GmbH
- Indication
- Metastatic or Locally Advanced EGFR mutated Non-Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active